AstraZeneca, GlaxoSmithKline infectious news

The EU's Innovative Medicines Initiative launched the NewDrugs4BadBugs grant program to fund development of new antibiotics against antibiotic-resistant bacteria, including products from GlaxoSmithKline and AstraZeneca. The program will also create an information hub to facilitate information sharing. The program will initially support Phase II

Read the full 446 word article

How to gain access

Continue reading with a
two-week free trial.